Immunomedics, Inc.
300 American Road
Morris Plains
New Jersey
07950-2450
United States
Tel: 201-605-8200
Fax: 973-605-8282
Website: http://www.immunomedics.com/
479 articles about Immunomedics, Inc.
-
Usama Malik, the former chief financial officer of Immunomedics, has been indicted for insider trading, five months after the U.S. Securities and Exchange Commission leveled charges.
-
Gilead Sciences is letting go of 114 employees following an underwhelming response to the results reaped so far from its $21 billion acquisition of Immunomedics in 2020.
-
Gilead has announced they are pulling cancer drug Zydelig (idelalisib) off the market for certain types of cancer after failing to complete follow-up clinical trials to confirm efficacy and safety.
-
The SEC announced charges against Usama Malik and his former live-in girlfriend Lauren S. Wood regarding an FDA decision during a trading black out.
-
Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma
10/12/2020
Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Trodelvy (sacituzumab govitecan-hziy) orphan status for the treatment of adult and pediatric patients with glioblastoma. “Glioblastoma is an aggressive cancer with a la
-
Clinical Catch-Up: September 21-25
9/28/2020
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look. -
The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.
-
Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer
9/19/2020
Trodelvy significantly reduced the risk of death by 52 percent, with a median overall survival(OS) of 12.1 months compared to6.7 months for standard single-agent chemotherapy
-
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer
9/19/2020
Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC)
-
The deal, announced Sunday, has been unanimously approved by the boards of directors of both companies.
-
Gilead Sciences to Acquire Immunomedics
9/13/2020
Gilead Adds TrodelvyTM, First-in-Class Antibody-Drug Conjugate Approved to Treat Triple-Negative Breast Cancer, With Promise in Other Forms of Breast Cancer and Additional Solid Tumors
-
Immunomedics Announces Key Oral Presentations at ESMO Virtual Congress 2020
9/9/2020
Breadth of presentations include i) Full results from ASCENT; ii) Final results from TROPHY U-01 cohort 1; iii) First results with Trodelvy™ in brain tumors
-
Immunomedics to Participate in Upcoming Healthcare Conferences - Sep 02, 2020
9/2/2020
Immunomedics, Inc., a leading biopharmaceutical company in the area of antibody-drug conjugates, announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to participate in virtual fireside chats at the following healthcare conferences
-
Immunomedics Announces FDA Approval of Samsung Biologics as Antibody Manufacturer for Trodelvy™Approval enhances long-term supply of Trodelvy
8/17/2020
Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved the Prior Approval Supplement (PAS) for Samsung Biologics to produce commercial-scale hRS7, the antibody used in Trodelvy (sacituzumab govitecan-hziy), at its manufacturing facilities in Incheon, South Korea.
-
Clinical Catch-Up: August 3-7
8/10/2020
It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look. -
Immunomedics Reports Second Quarter 2020 Results and Provides Corporate Update
8/5/2020
Confirmatory Phase 3 ASCENT study met primary endpoint of progression-free survival and key secondary endpoints of overall survival and objective response rate
-
Immunomedics to Report Second Quarter 2020 Results and Host Conference Call and Webcast on August 5, 2020
7/27/2020
Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that it will host a conference call on Wednesday, August 5, 2020 at 5:00 p.m. Eastern Time to discuss financial results for the second quarter of 2020 and provide a corporate update. To access the conference call, please dial (877) 303-2523 or (253) 237-1755 using the Con
-
Immunomedics Expands Collaboration with Roche Evaluating Trodelvy™ (sacituzumab govitecan-hziy) in Combination with Tecentriq® (atezolizumab) into Urothelial and Non-Small Cell Lung Cancers
7/13/2020
Immunomedics, Inc.(NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced an extension of its current clinical collaboration with Roche to evaluate Trodelvy, Immunomedics’ anti-Trop-2 ADC, in combination with Tecentriq,
-
Immunomedics announced today that its Phase III study involving Trodelvy met its primary endpoint of progress-free survival, as well as secondary endpoints, in patients with metastatic triple-negative breast cancer who have previously received at least two prior therapies.
-
Immunomedics Announces Positive Results from Phase 3 ASCENT Study of TRODELVY™ in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)
7/6/2020
Trodelvy significantly improved progression-free survival (PFS) and overall survival (OS) in previously-treated brain metastasis negative patients with advanced mTNBC The safety profile of Trodelvy was consistent with the FDA-approved label and no new safety signals were observed Trodelvy is the first antibody-drug conjugate (ADC) shown to improve clinical outcomes in people with relapsed or refractory mTNBC who have received two prior therapies sBLA submission seeking full approval